Canadian Cancer Trials Group Bulletins

Trial Management Group


Trial Activation

We are very pleased to announce that Canadian Cancer Trials Group GA.2 (AG0212OG) -- INTEGRATE - A Randomized Phase II Double-Blind Placebo-Controlled Study of Regorafenib in Refractory Advanced Esophago-Gastric Cancer (AEGC) -- was activated in Canada on Friday, December 14, 2012.

If you would like more information about this trial, please contact Barbara Graham, Study Coordinator, at 613-533-6430 or bgraham@ctg.queensu.ca.